Updated efficacy, safety, & PD-L1 status of patients with HR+, HER2- metastatic breast cancer administered abemaciclib plus pembrolizumab.Sara M. Tolaney, Hope S. Rugo, Suzanne R.L. Young et al.|Journal of Clinical Oncology|2018Cited by 40
First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.Yakun Wang, Lin Shen, Jifang Gong et al.|Journal of Clinical Oncology|2023Cited by 32
Clinical Response to Seribantumab, an Anti–Human Epidermal Growth Factor Receptor-3 Immunoglobulin 2 Monoclonal Antibody, in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma Harboring an <i>NRG1</i> FusionSubotheni Thavaneswaran, David M. Thomas, John P. Grady et al.|JCO Precision Oncology|2022Cited by 8